Peter L. Salgo, MD: I feel your pain, with just 1 diagnosis code. You’re relying on clinicians to speak to this. And is there a generalized agreement? Do all payers, and all providers, follow common ...

Secondary progressive multiple sclerosis (SPMS) can develop after relapsing-remitting multiple sclerosis (RRMS). It causes steady neurological decline, either with or without relapses. Switching from ...

Please provide your email address to receive an email when new articles are posted on . Tolebrutinib was associated with a 31% reduced risk for 6-month confirmed disability progression vs. placebo.

MRI activity appeared to be a more sensitive measure of disease activity in secondary progressive multiple sclerosis (SPMS) than relapses, an analysis of two datasets showed. "When we interrogated a ...

SAN DIEGO -- Investigational tolebrutinib slowed disability progression in people with non-relapsing secondary progressive multiple sclerosis (SPMS), the phase III HERCULES trial showed. The Bruton's ...

Mitoxantrone hydrochloride was the first FDA-approved medication for both secondary-progressive multiple sclerosis (MS) and progressive-relapsing MS. It’s also used to treat relapsing-remitting MS ...

Living with a chronic, progressive condition such as secondary progressive multiple sclerosis (SPMS) can affect both your physical and mental health. SPMS results in a gradual decline in function over ...

The number of cortical lesions at baseline may indicate a patient's risk of developing secondary progressive multiple sclerosis (MS), according to new research. Cortical lesions also may be an early ...

The Food and Drug Administration (FDA) has accepted for Priority Review the New Drug Application for tolebrutinib for the treatment of non-relapsing secondary progressive multiple sclerosis (nrSPMS).

Peter L. Salgo, MD: Before we use a very broad brush, which we’ve been doing, to discuss multiple sclerosis [MS], we’ve been able to get the subgroups and subtypes, right? There are different kinds of ...